The published clinical data - 19.5% average body weight reduction at 52 weeks across 1,131 patients, published in a peer-reviewed journal (this outcome reflects a retrospective analysis of program completers and should not be interpreted as typical or guaranteed) - is a published peer-reviewed evidence base, which is uncommon among telehealth GLP-1 platforms
Research suggests that GLP-1 medications may affect neurotransmitters like dopamine and serotonin, which play key roles in mood and motivation
Taking both medications together could increase the risk of side effects, such as nausea, vomiting, diarrhea, and constipation
96110 Developmental screening (e.g., Ages and Stages Questionnaire)
Our team can help eligible patients review insurance benefits and determine whether prior authorization requirements may apply
Initially, GLP-1s were developed to treat type 2 diabetes and were marketed for that purpose under brand names such as Ozempic (semaglutide), Rybelsus (semaglutide), Victoza (liraglutide), and Mounjaro (tirzepatide)